IL17A and psoriasis: The discovery of the central role of the IL-23/Th17 signaling axis in psoriasis pathogenesis has led to the development of biologics such as IL-23- or IL-17-blocking monoclonal antibodies, which represent perhaps the most effective line of treatment of psoriasis known to date [6,99,100].